Leerink Swann Starts Cyclacel Pharmaceuticals (CYCC) at Outperform; Multiple Opportunities Create Attractive Entry Point

Article Stock Quotes (1) Comments (1)

Leerink Swann initiates coverage on Cyclacel Pharmaceuticals (NASDAQ: CYCC) with an Outperform. PT $3.

Leerink analyst says, "With a foundation of targeting cell cycle pathways for the treatment of cancer, CYCC has recently advanced to become a "late stage" biotechnology company following the initiation of the pivotal Phase III SEAMLESS for lead clinical candidate, sapacitabine, in acute myeloid leukemia (AML) under an SPA. We see several clinical and corporate events over the next few months to years clarifying the possible commercial opportunities for the company's pipeline candidates, and potentially unlocking value in CYCC shares."

For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.

Shares of Cyclacel Pharmaceuticals closed at $1.20 yesterday, with a 52 week range of $1.16-$1.98.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Cyclacel (CYCC) Prices 6.67M Common Stock Offering
• Credit Suisse Starts New Residential Investment (NRZ) at Outperform
• Barclays Starts Crown Castle (CCI) at Equalweight

Create E-mail Alert Related Categories

New Coverage

Comments

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?